August 04, 2017
In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation
Case Number:
2:17-md-02785
Court:
Nature of Suit:
Multi Party Litigation:
Class Action, Multi-district Litigation
Judge:
Firms
- Foley & Lardner
- Squitieri & Fearon
- Law Offices of Ursula Taylor
- Gustafson Gluek
- DiCello Levitt
- Matthew G. Miller PC
- Spencer Fane
- Berman Tabacco
- Foulston Siefkin
- Sharp Law LLP
- Parker Waichman
- Burns Charest
- Sidley Austin
- Siegfried & Jensen
- Spragens Law
- Steven Williams Law
- Barnow & Associates
- Goldman Scarlato
- DLA Piper
- Saiber LLC
- Lockridge Grindal
- Blood Hurst
- Pritzker Levine
- Berkowitz Oliver
- Boies Schiller
- Hogan Lovells
- Baron & Budd
- Barton & Burrows
- Kaufman & Canoles
- Mehri & Skalet
- Beasley Allen
- Robbins Russell
- Kramer Levin
- King & Spalding
- Reed Smith
- Perkins Coie
- Yarmuth LLP
- Pallas Partners
- Lanier Law Firm
- Hagens Berman
- Lightfoot Franklin
- Hinkle Law Firm
- Robins Kaplan
- Carella Byrne
- Marion's Inn
- Ali & Lockwood
- Strategic Health Law
- Dollar Burns
- Butler Prather
- Fredrikson & Byron
- Bradford & Wilson
- Gibbons PC
- Williams & Connolly
- Horn Aylward
- Joseph Saveri Law Firm
- Keller Rohrback
- Groom Law Group
- Bush Seyferth
- Wagstaff & Cartmell
- Weil Gotshal
- Gibson Dunn
- Shook Hardy
- Lowey Dannenberg
- Wilson Sonsini
- Levi & Korsinsky
- Lathrop GPM
- Robbins Geller
- GM Law PC
- Clark Hill
- Holland & Knight
- Goodwin Procter
- Latham & Watkins
- Mayer Brown
- White & Case
- Willkie Farr
Companies
- Optum Inc.
- Amerigroup Corp.
- Change Healthcare Inc.
- MedImpact Healthcare Systems Inc.
- Express Scripts Holding Co.
- Aetna Inc.
- Meridian Medical Technologies Inc.
- Coventry Health Care Inc.
- The Segal Co. Inc.
- Blue Cross Blue Shield Association
- Viatris Inc.
- Humana Inc.
- OptumRx Inc.
- CVS Health Corp.
- Centene Corp.
- King Pharmaceuticals Inc.
- Sanofi
- UnitedHealth Group Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
March 14, 2022
Judge OKs $264M Deal Ending Mylan EpiPen Price-Hike Suit
A Kansas federal court has preliminarily approved a $264 million deal that would end claims that Mylan colluded with Pfizer Inc. to obstruct generic versions of the EpiPen, the emergency drug used to treat severe allergic reactions, from entering the market.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what鈥檚 happening with clients, competitors, practice areas, and industries. 极速赛车 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login